Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan
© 2022. The Author(s), under exclusive licence to The Japanese Society of Nephrology..
BACKGROUND: Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear.
METHODS: This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 m2) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission.
RESULTS: Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality.
CONCLUSIONS: On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Clinical and experimental nephrology - 26(2022), 10 vom: 03. Okt., Seite 974-981 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sato, Ryosuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 20.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10157-022-02240-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341793612 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341793612 | ||
| 003 | DE-627 | ||
| 005 | 20231226012606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10157-022-02240-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341793612 | ||
| 035 | |a (NLM)35657437 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sato, Ryosuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 20.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to The Japanese Society of Nephrology. | ||
| 520 | |a BACKGROUND: Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear | ||
| 520 | |a METHODS: This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 m2) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission | ||
| 520 | |a RESULTS: Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality | ||
| 520 | |a CONCLUSIONS: On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical outcome | |
| 650 | 4 | |a Kidney dysfunction | |
| 700 | 1 | |a Matsuzawa, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Hisao |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Kazuo |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuboi, Nobuo |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoo, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kirigaya, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Fukui, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tsukahara, Kengo |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Iwabuchi, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Saka, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kashihara, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Kouichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental nephrology |d 1998 |g 26(2022), 10 vom: 03. Okt., Seite 974-981 |w (DE-627)NLM096492473 |x 1437-7799 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:10 |g day:03 |g month:10 |g pages:974-981 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10157-022-02240-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 10 |b 03 |c 10 |h 974-981 | ||